+ Watch MDVN
on My Watchlist
A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.
MEDIVATION INC, ticker MDVN, has a TTM ROE calculated by Zacks of 89,87%. It's one of my LONG picks.
Strong revenue growth from Xtandi and recent label expansion mode well for this stock.
At a stock price of 47 times book value, an unprofitable business and 162 dollars of debt for every dollar of equity what could possibly go wrong?
Prostate cancer is not going away anytime soon and this drug is making a positive impact on patients. Easier to take 4 pills in the morning than sit in an infusion center for 3 hours. Also doesn't require Prednisone which is a plus over its rival J & J's Zytiga.
As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.
MDVN's Xtandi has data coming for a pre-chemo prostate cancer indication and as a potential first line treatment for Xtandi too. Positive data from those trials would expand the patient pool and could significantly grow sales.
Not much competition from other drug makers for their prostate cancer drug for probably a year or so.
This drug company doesn't appear to have anything in its portfolio to warrant this valuation.
Will rule in prostate cancer field.
high relative strenght
went up 237% for portefeille.
new prostate drug
Another overinflated biotech that hasn't proven anything as of yet.
MDV3100 looks as if it might take much of the prostate cancer market and work in breast cancer also. Sales of 2 billion on the low side. Someone will buy them after the launch. 100+ by the end of 2012. Buy on any dips and add slowly.
Phase 3 data coming soon..... And will likely be great
Hopefully Dimebon has now provided enough failures to reduce its contribution to Medivation's enterprise value to zero. The new central story is the promising prostate cancer drug MDV3100 . In June the company reported preliminary data from an MD Anderson study of MDV3100 showing that 45% of 55 advanced prostate ca patients experienced at least a 50% decrease in PSA levels. An interim analysis of the AFFIRM phase III placebo controlled trial of MDV3100 in castration-resistant prostate cancer may be performed before the end of the year. The share price hasn't seen 15 since February, when encouraging data for MDV3100 first started to get noticed.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions